Cargando…
Ruthenium-Based Photoactivated Chemotherapy
[Image: see text] Ruthenium(II) polypyridyl complexes form a vast family of molecules characterized by their finely tuned photochemical and photophysical properties. Their ability to undergo excited-state deactivation via photosubstitution reactions makes them quite unique in inorganic photochemistr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623564/ https://www.ncbi.nlm.nih.gov/pubmed/37846939 http://dx.doi.org/10.1021/jacs.3c01135 |
_version_ | 1785130764841517056 |
---|---|
author | Bonnet, Sylvestre |
author_facet | Bonnet, Sylvestre |
author_sort | Bonnet, Sylvestre |
collection | PubMed |
description | [Image: see text] Ruthenium(II) polypyridyl complexes form a vast family of molecules characterized by their finely tuned photochemical and photophysical properties. Their ability to undergo excited-state deactivation via photosubstitution reactions makes them quite unique in inorganic photochemistry. As a consequence, they have been used, in general, for building dynamic molecular systems responsive to light but, more particularly, in the field of oncology, as prodrugs for a new cancer treatment modality called photoactivated chemotherapy (PACT). Indeed, the ability of a coordination bond to be selectively broken under visible light irradiation offers fascinating perspectives in oncology: it is possible to make poorly toxic agents in the dark that become activated toward cancer cell killing by simple visible light irradiation of the compound inside a tumor. In this Perspective, we review the most important concepts behind the PACT idea, the relationship between ruthenium compounds used for PACT and those used for a related phototherapeutic approach called photodynamic therapy (PDT), and we discuss important questions about real-life applications of PACT in the clinic. We conclude this Perspective with important challenges in the field and an outlook. |
format | Online Article Text |
id | pubmed-10623564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-106235642023-11-04 Ruthenium-Based Photoactivated Chemotherapy Bonnet, Sylvestre J Am Chem Soc [Image: see text] Ruthenium(II) polypyridyl complexes form a vast family of molecules characterized by their finely tuned photochemical and photophysical properties. Their ability to undergo excited-state deactivation via photosubstitution reactions makes them quite unique in inorganic photochemistry. As a consequence, they have been used, in general, for building dynamic molecular systems responsive to light but, more particularly, in the field of oncology, as prodrugs for a new cancer treatment modality called photoactivated chemotherapy (PACT). Indeed, the ability of a coordination bond to be selectively broken under visible light irradiation offers fascinating perspectives in oncology: it is possible to make poorly toxic agents in the dark that become activated toward cancer cell killing by simple visible light irradiation of the compound inside a tumor. In this Perspective, we review the most important concepts behind the PACT idea, the relationship between ruthenium compounds used for PACT and those used for a related phototherapeutic approach called photodynamic therapy (PDT), and we discuss important questions about real-life applications of PACT in the clinic. We conclude this Perspective with important challenges in the field and an outlook. American Chemical Society 2023-10-17 /pmc/articles/PMC10623564/ /pubmed/37846939 http://dx.doi.org/10.1021/jacs.3c01135 Text en © 2023 The Author. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Bonnet, Sylvestre Ruthenium-Based Photoactivated Chemotherapy |
title | Ruthenium-Based
Photoactivated Chemotherapy |
title_full | Ruthenium-Based
Photoactivated Chemotherapy |
title_fullStr | Ruthenium-Based
Photoactivated Chemotherapy |
title_full_unstemmed | Ruthenium-Based
Photoactivated Chemotherapy |
title_short | Ruthenium-Based
Photoactivated Chemotherapy |
title_sort | ruthenium-based
photoactivated chemotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623564/ https://www.ncbi.nlm.nih.gov/pubmed/37846939 http://dx.doi.org/10.1021/jacs.3c01135 |
work_keys_str_mv | AT bonnetsylvestre rutheniumbasedphotoactivatedchemotherapy |